Publish in this journal
Journal Information
Vol. 62. Issue 11.
Pages 1217-1220 (November 2009)
Share
Share
Download PDF
More article options
Vol. 62. Issue 11.
Pages 1217-1220 (November 2009)
DOI: 10.1016/S1885-5857(09)73347-X
Full text access
Pacemaker Therapy in Hypertrophic Obstructive Cardiomyopathy: Still Awaiting the Evidence
El tratamiento con marcapasos de la miocardiopatía hipertrófica obstructiva: a la espera de la evidencia
Visits
7365
William J. McKennaa, Juan Pablo Kaskib
a The Heart Hospital, University College London, London, United Kingdom
b The Heart Hospital, University College London, London, United Kingdom
This item has received
7365
Visits
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

The initial descriptions of hypertrophic cardiomyopathy (HCM) focused on the presence of left ventricular (LV) outflow tract obstruction as a defining feature of the condition.1-6 The use of echocardiography, which emerged as the gold standard technique for non-invasive assessment of the heart from the 1970s onwards, subsequently suggested that only a minority of patients have evidence of LV outflow tract obstruction at rest.7,8 However, more recent studies have shown that up to 70%-75% of patients with HCM have obstruction either at rest (25%-30%) or upon provocation.9,10 This observation has important clinical implications. First, it is well recognized that LV outflow tract obstruction can cause symptoms, including exertional dyspnoea, angina, and syncope or presyncope, resulting from acute reductions in cardiac output, with elevated left ventricular filling pressures and myocardial ischaemia. Symptoms in obstructive HCM are most commonly exertional therefore, the non-invasive evaluation of LV outflow tract obstruction should include provocation manoeuvres such as upright exercise or Valsalva. Furthermore, patients with LV outflow tract obstruction have worse overall, HCM-related and sudden death-free survival than those without obstruction.11-13 The abolition/reduction of LVOTO, and the relief of symptoms associated with it, is therefore a key feature of the management of patients with HCM.

Mechanism of Left Ventricular Outflow Tract Obstruction

Our understanding of the mechanisms that result in obstruction to the LV outflow in HCM has evolved substantially over time.14 Initial theories that obstruction was the result of a muscular ring that contracted during ventricular systole15,16 were subsequently disproved; the advent of M-mode echocardiography identified systolic anterior motion (SAM) of the mitral valve as a key feature of obstructive HCM.4 The mechanisms for this phenomenon, however, have been the subject of debate over the past 20 years. Until recently, the most widely accepted explanation for SAM has been that septal hypertrophy and narrowing of the LV outflow tract result in a high velocity zone anterior to the mitral valve that causes its tip to be sucked against the septum by the Venturi effect.17 This hypothesis, however, does not explain a number of features associated with SAM; in particular, the fact that it begins before aortic valve opening and that it can occur in patients with little or no septal hypertrophy. More recent data suggest that, as a result of septal hypertrophy, flow from the ventricular cavity to the outflow tract occurs across the mitral valve, therefore driving it rather than sucking it into the septum.18 In this model, anterior displacement of the papillary muscles and sub-mitral apparatus are necessary to create sufficient leaflet slack to allow the mitral leaflets to move forward in systole.

Current Treatment Strategies for Obstructive Hypertrophic Cardiomyopathy

The management of LV outflow tract obstruction in patients with HCM is directed towards the relief of lifestyle-limiting symptoms.19 Pharmacological therapy is the mainstay of treatment for symptomatic LV outflow tract obstruction and often produces adequate results. However, symptoms remain in a small proportion of patients, requiring invasive alternative strategies. The gold standard therapy for symptomatic outflow tract obstruction refractory to medical treatment is surgical myectomy. In the hands of experienced centres, this procedure results in near or complete abolition of the LV outflow tract gradient in over 90% of patients, with low morbidity and mortality rates of less than 1%.13,20 Furthermore, recent observational data suggest a survival benefit in patients who have undergone surgical myectomy compared with those whose LV outflow tract obstruction has been managed without surgery.13 A less invasive alternative to surgical myectomy is percutaneous transcatheter alcohol septal ablation, first described in 1995.21 Compared to surgical myectomy, symptom relief and gradient reduction with alcohol septal ablation are similar, but complication rates (particularly complete heart block, requiring implantation of permanent pacing systems) and mortality are higher.22-26 In patients under the age of 65 years, recurrence of symptoms and mortality rates are almost doubled compared with surgical myectomy patients.27

Role of Dual Chamber Pacing in Obstructive Hypertrophic Cardiomyopathy

The potential beneficial effects of pacing in patients with hypertrophic obstructive cardiomyopathy were first reported in the late 1960s and early 1970s.28-30

In these reports, right ventricular pacing reduced the LV outflow tract gradient, but at the expense of a drop in systolic aortic pressure and stroke volume. Subsequent studies using atrio-ventricular sequential pacing showed better haemodynamic results,31 associated with improved functional capacity in some patients.32 However, it was not until Jeanrenaud and colleagues' study in 1992, evaluating the acute and medium-term effects of dual chamber pacing in 13 patients with symptomatic obstructive HCM refractory to pharmacological treatment,33 that pacemaker therapy emerged as a potential treatment for symptomatic obstructive disease. In this study, dual chamber pacing significantly reduced LV outflow tract gradient with no change in aortic pressure or cardiac output, and over a follow-up period of up to 62 months, pacing resulted in a significant reduction in symptoms (chest pain and dyspnoea). The proposed mechanism for the beneficial effects of pacing was apical pre-excitation, resulting in attenuated septal contraction and delaying the onset of mitral leaflet-septal contact. The atrioventricular interval was identified as the key factor, needing to be long enough to allow optimum LV filling but shorter than the native atrioventricular interval to preserve apical pre-excitation. This landmark report was followed by other single-centre series that confirmed the acute and longer-term reduction in LV outflow gradients and symptomatic improvement.34 However, 3 subsequent multi-centre randomized crossover trials produced less promising results.35-37 Although all 3 studies showed a modest reduction in LV outflow tract gradient and subjective symptomatic improvement in some patients, this was not accompanied by objective improvements in cardiovascular performance and mean residual gradients were above 30 mm Hg. Furthermore, a substantial placebo effect was documented in all 3 studies.36-38 As a result, pacemaker therapy was relegated to class IIb indication for the treatment of obstructive HCM, and attention was turned to percutaneous alcohol septal ablation as a potential alternative to surgical myectomy. The results of the elegant long-term study by Sandín M et al reported in this issue of Revista Española de Cardiología39 appear to support the limited role of pacemaker therapy in the management of obstructive HCM. In keeping with the multicentre trials, although there was a reduction in the LV outflow tract gradient with pacing, this only translated into a subjective symptomatic improvement in less than half the patients, and there was no concomitant improvement in objectively assessed functional capacity. However, pacing remains an attractive therapeutic strategy, given its minimally invasive nature and substantially lower rate of procedure-related morbidity and mortality compared to surgery and transcatheter therapies. In addition, as pointed out by Sandín M et al in this issue,39 expertise in surgical and transcatheter gradient reduction procedures is not universal, whilst pacemaker implantation is more widely available. A small subgroup of older patients do appear to show objective improvements in functional capacity,36 a finding supported by a recent 10-year follow-up study from Hospital Universitario Vall d'Hebron, Barcelona, of 50 patients with a mean age of 62 years, which showed a significant gradient reduction, subjective and objective improvements in cardiovascular performance, and better health-related quality of life.40 Therefore, although not the first-line treatment for LV outflow tract obstruction in HCM, dual chamber pacing does remain a useful therapy for patients at very high risk for surgical or transcatheter therapy, or in whom these options are not available.

Future Directions

The 50 years since the initial description of obstructive HCM have seen dramatic improvements in the assessment and management of LV outflow tract obstruction.41 Nevertheless, the goal of treatment remains the same: the relief of symptoms and improvement in quality of life. Any novel treatment for obstructive HCM, therefore, must produce significant reduction in subjectively assessed symptoms and objectively assessed cardiovascular performance. In addition, procedure-related morbidity and mortality should be low. Dual chamber pacing is the only therapy for HCM to have been subjected to rigorous, placebo-controlled randomized trials, with less than promising results. Current data suggest that older patients with mild, localized septal hypertrophy or angulated septa are those most likely to benefit from pacing. Data do not suggest, however, that any other specific subgroups will benefit.

SEE ARTICLE ON PAGES 1233-9


Correspondence: W.J. McKenna, MD,
The Heart Hospital, University College London Hospitals,
16-18 Westmoreland Street, London W1G 8PH, United Kingdom
E-mail: william.mckenna@uclh.org

Bibliography
[1]
Brock R..
Functional obstruction of the left ventricle..
[2]
Frank S, Braunwald E..
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history..
Circulation, 37 (1968), pp. 759-88
[3]
Goodwin JF, Hollman A, Cleland WP, Teare D..
Obstructive cardiomyopathy simulating aortic stenosis..
Br Heart J, 22 (1960), pp. 403-14
[4]
Shah PM, Gramiak R, Kramer DH..
Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy..
Circulation, 40 (1969), pp. 3-11
[5]
Teare D..
Asymmetrical hypertrophy of the heart in young adults..
Br Heart J, 20 (1958), pp. 1-8
[6]
Wigle ED, Heimbecker RO, Gunton RW..
Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis..
Circulation, 26 (1962), pp. 325-40
[7]
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE..
Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults..
Circulation, 92 (1995), pp. 785-9
[8]
Maron BJ, Gottdiener JS, Epstein SE..
Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients..
Am J Cardiol, 48 (1981), pp. 418-28
[9]
Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al..
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction..
Circulation, 114 (2006), pp. 2232-9
[10]
Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, et al..
Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy..
Heart, 94 (2008), pp. 1288-94
[11]
Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R, et al..
Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy..
Eur Heart J, 27 (2006), pp. 1933-41
[12]
Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al..
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy..
N Engl J Med, 348 (2003), pp. 295-303
[13]
Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al..
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy..
J Am Coll Cardiol, 46 (2005), pp. 470-6
[14]
Ommen S, R Nishimura..
What causes outflow tract obstruction in hypertrophic cardiomyopathy? Heart..
Jul 22, 2009, ([Epub ahead of print]),
[15]
Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr..
, Morrow AG. Idiopathic Hypertrophic Subaortic Stenosis. I. A Description of the Disease Based Upon an Analysis of 64 Patients..
Circulation, 30 Suppl 4 (1964), pp. 3-119
[16]
Morrow AG, Lambrew CT, Braunwald E..
Idiopathic Hypertrophic Subaortic Stenosis. Ii. Operative Treatment and the Results of Pre- and Postoperative Hemodynamic Evaluations..
Circulation, 30 Suppl 4 (1964), pp. 120-51
[17]
Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al..
Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review..
Prog Cardiovasc Dis, 28 (1985), pp. 1-83
[18]
Jiang L, Levine RA, King ME, Weyman AE..
An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations..
Am Heart J, 113 (1987), pp. 633-44
[19]
Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al..
American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines..
Eur Heart J, 24 (2003), pp. 1965-91
[20]
Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al..
Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy..
Circulation, 111 (2005), pp. 2033-41
[21]
Sigwart U..
Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy..
Lancet, 346 (1995), pp. 211-4
[22]
Faber L, A Meissne.r, P Ziemsse.n, H Seggewiss..
Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients..
Heart, 83 (2000), pp. 326-31
[23]
Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, et al..
Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes..
Eur Heart J, 23 (2002), pp. 1617-24
[24]
Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al..
Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy..
J Am Coll Cardiol, 38 (2001), pp. 1701-6
[25]
Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, et al..
Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery..
J Am Coll Cardiol, 38 (2001), pp. 1994-2000
[26]
Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, et al..
Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score..
J Thorac Cardiovasc Surg, 129 (2005), pp. 351-8
[27]
Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al..
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy..
[28]
Hassenstein P, Storch HH, Schmitz W..
[Results of electrical pacing in patients with hypertrophic obstruction cardiomyopathy (author''s transl)]..
Thoraxchir Vask Chir, 23 (1975), pp. 496-8
[29]
Hassenstein P, Wolter HH..
[Therapeutic control of a threatening stage of idiopathic hypertrophic subaortic stenosis]..
Verh Dtsch Ges Kreislaufforsch, 33 (1967), pp. 242-6
[30]
Rothlin M, Moccetti T..
[Influencing of the muscular subaortic stenosis by intraventricular stimulus propagation]..
Verh Dtsch Ges Kreislaufforsch, 37 (1971), pp. 411-5
[31]
Duck HJ, Hutschenreiter W, Pankau H, Trenckmann H..
[Atrial synchronous ventricular stimulation with reduced a.v. delay time as a therapeutic principle in hypertrophic obstructive cardiomyopathy]..
Z Gesamte Inn Med, 39 (1984), pp. 437-47
[32]
McDonald K, McWilliams E, O''Keeffe B, Maurer B..
Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy..
Eur Heart J, 9 (1988), pp. 893-8
[33]
Jeanrenaud X, Goy JJ, Kappenberger L..
Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy..
Lancet, 339 (1992), pp. 1318-23
[34]
Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D..
Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy..
Circulation, 90 (1994), pp. 2731-42
[35]
Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, et al..
Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group..
Eur Heart J, 18 (1997), pp. 1249-56
[36]
Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS..
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)..
Circulation, 99 (1999), pp. 2927-33
[37]
Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al..
Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial..
J Am Coll Cardiol, 29 (1997), pp. 435-41
[38]
Linde C, Gadler F, Kappenberger L, Ryden L..
Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy..
Am J Cardiol, 83 (1999), pp. 903-7
[39]
Sandín M, Marín F, Cambronero F, Climent V, Caro C, Martínez JG, et al..
¿Existe un efecto beneficioso a largo plazo con el tratamiento con marcapasos en la miocardiopatía hipertrófica obstructiva severa? Rev Esp Cardiol..
, 62 (2009), pp. 1233-9
[40]
Galve E, Sambola A, Saldana G, Quispe I, Nieto E, Diaz A, et al..
Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy. A 10-year follow-up study. Heart..
2009 May 28, ([Epub ahead of print]),
[41]
McKenna WJ, Sen-Chowdhry S..
De Teare a nuestros días: una odisea de cincuenta años en la miocardiopatía hipertrófica, un paradigma en la lógica del proceso de descubrimiento..
Rev Esp Cardiol, 61 (2008), pp. 1239-44
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.